DGAP-News

STADA Arzneimittel AG: Figures for the first half of 2015 benefit from substantially improved development in Q2/2015 - Central Europe as well as Asia/Pacific & MENA with excellent development, CIS/Eastern Europe stabilized considerably - Seite 2

1,025.9 million (1-6/2014: Euro 1,002.8 million).

Sales of the core segment Generics grew by 3 percent to Euro 615.3 million
in the reporting period (1-6/2014: Euro 598.7 million). This development
was based for the most part on a strong sales growth of the German
subsidiary ALIUD PHARMA GmbH as well as a substantially positive sales
development of the British, Spanish, Dutch and Vietnamese companies. An
opposite effect resulted from sales generated with generics in the Russian
market, which belongs to the market region CIS/Eastern Europe, and in the
Belgian and French markets, which belong to the market region Central
Europe. Generics contributed 60.0 percent to Group sales (1-6/2014: 59.7
percent). Sales of the core segment Branded Products in the reporting
period recorded an increase of 2 percent to Euro 389.3 million
(1-6/2014: Euro 381.6 million). The increase was mainly attributable to the
development in the United Kingdom and Vietnam. Sales generated with branded
products in the Russian market, which belongs to the market region
CIS/Eastern Europe, showed a contrary development. Branded products
contributed 37.9 percent to Group sales (1-6/2014: 38.1 percent).

Development of earnings
Both reported key earnings figures and adjusted key earnings figures
recorded a decrease in the reporting period. This development was primarily
based on negative currency effects from the considerable weakness of the
Russian ruble and the strong devaluation of the Ukrainian hryvnia.
Furthermore, the decreased purchase power associated with the devaluation
of the Russian ruble and the increasing inflation had an impact on demand
patterns in the Russian self-pay market.

Reported operating profit decreased by 8 percent to Euro 112.1 million in
the reporting period (1-6/2014: Euro 121.2 million). Reported EBITDA
declined by 6 percent to Euro 181.4 million (1-6/2014: Euro 192.1 million).
Reported net income recorded a decrease of 20 percent to Euro 53.6 million
(1-6/2014: Euro 66.8 million).

After adjusting the key earnings figures for influences distorting the
period comparison resulting from one-time special effects, adjusted
operating profit decreased by 9 percent in the first 6 months of 2015 to
Euro 138.1 million (1-6/2014: Euro 152.2 million). Adjusted EBITDA showed a
decline of 9 percent to Euro 189.2 million (1-6/2014: Euro 208.3 million).
Adjusted net income decreased by 6 percent to Euro 85.0 million (1-6/2014:
Euro 90.1 million).

The net debt to adjusted EBITDA ratio in the first half of 2015 was at 3.7